Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elementis plc stock logo
ELMTY
Elementis
$7.48
$7.53
$4.85
$7.58
$1.10B142 shsN/A
GREE, Inc. stock logo
GREZF
GREE
$6.20
$6.20
$5.72
$9.01
$1.07B0.03N/AN/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
$1.86
-1.6%
$1.51
$0.82
$1.96
N/A1.5738,829 shs15,656 shs
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
$3.68
$3.52
$2.17
$3.75
N/A0.98N/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$26.85
$32.37
$26.85
$46.26
N/A0.213 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elementis plc stock logo
ELMTY
Elementis
0.00%-1.32%-0.40%+3.46%+24.67%
GREE, Inc. stock logo
GREZF
GREE
0.00%0.00%0.00%0.00%0.00%
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
-1.50%-0.44%+14.92%+55.14%+106.86%
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
0.00%0.00%0.00%+8.24%+7.29%
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.00%0.00%-8.33%-39.16%-40.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elementis plc stock logo
ELMTY
Elementis
N/AN/AN/AN/AN/AN/AN/AN/A
GREE, Inc. stock logo
GREZF
GREE
N/AN/AN/AN/AN/AN/AN/AN/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
N/AN/AN/AN/AN/AN/AN/AN/A
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
N/AN/AN/AN/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elementis plc stock logo
ELMTY
Elementis
N/AN/AN/AN/A
GREE, Inc. stock logo
GREZF
GREE
N/AN/AN/AN/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
3.00
BuyN/AN/A
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
3.00
BuyN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elementis plc stock logo
ELMTY
Elementis
$713.40M1.54$0.82 per share9.15$5.77 per share1.30
GREE, Inc. stock logo
GREZF
GREE
N/AN/AN/AN/AN/AN/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
$735.64MN/A$0.28 per share6.70$1.41 per shareN/A
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
$1.38BN/A$0.60 per share6.17$1.86 per shareN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$171.15MN/A$3.23 per share8.30$13.04 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elementis plc stock logo
ELMTY
Elementis
$26.50MN/A0.0011.87N/AN/AN/AN/AN/A
GREE, Inc. stock logo
GREZF
GREE
N/AN/A0.00N/AN/AN/AN/AN/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
$2.96MN/A0.00N/AN/AN/AN/AN/A
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
$108.85MN/A0.009.20N/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
$1.23MN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elementis plc stock logo
ELMTY
Elementis
N/AN/AN/AN/AN/A
GREE, Inc. stock logo
GREZF
GREE
N/AN/AN/AN/AN/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
N/AN/AN/AN/AN/A
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
N/AN/AN/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/A

Latest MCRUF, ELMTY, GREZF, HCHDF, and PHMMF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2024
Elementis plc stock logo
ELMTY
Elementis
$0.07175/2/20245/3/20246/17/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elementis plc stock logo
ELMTY
Elementis
0.31
2.20
1.17
GREE, Inc. stock logo
GREZF
GREE
N/AN/AN/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
N/AN/AN/A
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
N/AN/AN/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
0.13
3.01
2.61

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Elementis plc stock logo
ELMTY
Elementis
N/A
GREE, Inc. stock logo
GREZF
GREE
N/A
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
N/A
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
N/A
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Elementis plc stock logo
ELMTY
Elementis
1,281146.96 millionN/ANot Optionable
GREE, Inc. stock logo
GREZF
GREE
1,610173.37 millionN/ANot Optionable
Hochschild Mining plc stock logo
HCHDF
Hochschild Mining
3,598N/AN/ANot Optionable
Morgan Advanced Materials plc stock logo
MCRUF
Morgan Advanced Materials
9,000N/AN/ANot Optionable
Pharma Mar, S.A. stock logo
PHMMF
Pharma Mar
509N/AN/ANot Optionable

MCRUF, ELMTY, GREZF, HCHDF, and PHMMF Headlines

SourceHeadline
A Path to the CMP Designation: Pharma Forum in TampaA Path to the CMP Designation: Pharma Forum in Tampa
meetingsnet.com - March 20 at 4:59 PM
Pharming Group’s Strong Performance and Growth Prospects Justify Buy RatingPharming Group’s Strong Performance and Growth Prospects Justify Buy Rating
markets.businessinsider.com - March 18 at 1:46 PM
Mar-a-lagoMar-a-lago
newsweek.com - March 16 at 10:00 AM
Pharmas ad theme at this year’s Oscar saw a big shift from 2023Pharma's ad theme at this year’s Oscar saw a big shift from 2023
fiercepharma.com - March 13 at 10:21 AM
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back painPersica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
markets.businessinsider.com - March 7 at 7:03 AM
PharmaKure partners with Sheffield Hallam University to develop epigenetic markers for Alzheimer’s disease predictionPharmaKure partners with Sheffield Hallam University to develop epigenetic markers for Alzheimer’s disease prediction
news-medical.net - March 4 at 4:04 AM
Pharma Mar SAU (PHMR)Pharma Mar SAU (PHMR)
investing.com - February 17 at 3:04 AM
Pharma Forum 2024: Special Elements On and Off SitePharma Forum 2024: Special Elements On and Off Site
meetingsnet.com - February 14 at 6:15 PM
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma MarketPfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
investorplace.com - February 1 at 2:03 PM
Two new databases combine computer science and pharmaceutical researchTwo new databases combine computer science and pharmaceutical research
msn.com - January 9 at 1:32 PM
First West Africa Healthcare, Lab, & Pharma Week 2024 To Hold In NigeriaFirst West Africa Healthcare, Lab, & Pharma Week 2024 To Hold In Nigeria
msn.com - November 29 at 11:26 PM
Pharma Mar SA PHMPharma Mar SA PHM
morningstar.com - November 6 at 12:33 AM
Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024Piramal Pharma Limited Announces Consolidated Results for Q2 and H1 FY2024
markets.businessinsider.com - October 28 at 9:31 AM
A framework for screening pharmaceuticals and personal care products in landfill leachatesA framework for screening pharmaceuticals and personal care products in landfill leachates
phys.org - October 26 at 7:32 PM
Sort Through Highly Undervalued Pharma Stocks to Find the Best Pharmaceutical Stocks, 2023Sort Through Highly Undervalued Pharma Stocks to Find the Best Pharmaceutical Stocks, 2023
industryleadersmagazine.com - September 23 at 12:07 AM
Targeted Education at Pharma Forum EMEA and U.S.Targeted Education at Pharma Forum EMEA and U.S.
meetingsnet.com - September 20 at 7:08 PM
China’s Hengrui Pharma Licenses New Asthma Drug to US’ One Bio for Up to USD1 BillionChina’s Hengrui Pharma Licenses New Asthma Drug to US’ One Bio for Up to USD1 Billion
yicaiglobal.com - August 15 at 9:35 AM
Pharma Mar S.A.Pharma Mar S.A.
barrons.com - July 15 at 3:26 PM
Yifan PharmaceuticalYifan Pharmaceutical
forbes.com - June 21 at 8:33 PM
FTC expands PBM probe, orders records from Emisar PharmaFTC expands PBM probe, orders records from Emisar Pharma
modernhealthcare.com - June 8 at 10:34 PM
PHM.MC - Pharma Mar, S.A.PHM.MC - Pharma Mar, S.A.
finance.yahoo.com - June 6 at 7:41 PM
Austrian study shows transparency of pharmaceutical sponsorship for patient initiatives increased significantlyAustrian study shows transparency of pharmaceutical sponsorship for patient initiatives increased significantly
medicalxpress.com - May 22 at 3:37 PM
‘Phar­ma Bro’ Mar­tin Shkre­lis com­pa­nies file for bank­rupt­cy‘Phar­ma Bro’ Mar­tin Shkre­li's com­pa­nies file for bank­rupt­cy
endpts.com - May 10 at 6:01 PM
NEEDHAM & COMPANY INC. Maintains Pharma Mar (XMAD:PHM) Buy RecommendationNEEDHAM & COMPANY INC. Maintains Pharma Mar (XMAD:PHM) Buy Recommendation
msn.com - April 22 at 8:50 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Elementis logo

Elementis

OTCMKTS:ELMTY
Elementis plc operates as a specialty chemical company in the United Kingdom, rest of Europe, North America, and internationally. It operates in two segments, Performance Specialties and Personal Care. The Performance Specialties segment engages in the production of rheological modifiers and additives for decorative and industrial coatings; and production and supply of talc for use in plastics, coatings, technical ceramics, and paper sectors. The Personal Care segment provides rheological modifiers and compounded products, including active ingredients for antiperspirants (AP) deodorants for personal care manufacturers. The company offers personal care products for antiperspirants, color cosmetics, and skin care applications; and performance specialties products for architectural coatings, adhesives, sealants and construction additives, and talc applications. Elementis plc was founded in 1844 and is headquartered in London, the United Kingdom.
GREE logo

GREE

OTCMKTS:GREZF
GREE, Inc. operates Internet entertainment, investment, and incubation business in Japan and internationally. It develops and operates various smartphone games under the GREE, WFS, Pokelabo, and GREE Entertainment brands; and engages with anime production committees to develop original contents domestically and internationally. The company also offers REALITY, a metaverse for smartphone for individuals to turn themselves into digital avatar and stream various contents, and VTuber business that allows streamers to host live digital performances, play games, and chat services; and REALITY XR cloud, a cloud solution platform that enables corporate customers to build their own metaverse using 3DCG and XR technologies, as well as develop and publish blockchain games. In addition, it provides Marketing DX a service designed to accompany the evolution of client companies and business growth; Operation DX that manages customer relationships, quality control, and risks associated with business development; and DDM, an analytics platform to restructures disorganized internal data by incorporating real-time visualization. Further, the company offers aumo that provides travel and lifestyle information content including latest information on restaurants, shopping, and travel, as well as user reviews on various stores and other facilities; and support for creation of sales promotion pages, access analysis, and post and dissemination of store and facility information. Additionally, it provides jobda for job-related information; LIMIA, an on-;one magazines that features home and living lifestyle content; MINE, an on-line video magazine that features women's fashion, beauty and lifestyle content; and ARINE, a on-line magazine for young women. The company also offers DADAN to deliver the entertainment of manga; STUDIO DADAN to plan and produce manga content; and invests in internet and IT fields. GREE, Inc. was incorporated in 2004 and is headquartered in Tokyo, Japan.
Hochschild Mining logo

Hochschild Mining

OTCMKTS:HCHDF
Hochschild Mining plc, a precious metals company, engages in the exploration, mining, processing, and sale of gold and silver in the Americas. The company holds 100% interests in the Inmaculada gold/silver underground operation and Pallancata silver/gold property, which are located in the Department of Ayacucho in southern Peru. It also holds a 51% interest in the San Jose silver/gold mine located in Argentina. In addition, the company has a portfolio of projects located across Peru, Argentina, Mexico, United States, Canada, Brazil, and Chile. Further, it is involved in the power generation business. Hochschild Mining plc was founded in 1911 and is based in London, the United Kingdom.
Morgan Advanced Materials logo

Morgan Advanced Materials

OTCMKTS:MCRUF
Morgan Advanced Materials plc operates as a materials science and application engineering company primarily the United Kingdom. It serves customers in the industrial, transportation, petrochemical and chemical, energy, semiconductor and electronics, healthcare, and security and defense markets. The company was formerly known as The Morgan Crucible Company plc and changed its name to Morgan Advanced Materials plc in March 2013. Morgan Advanced Materials plc was founded in 1856 and is headquartered in Windsor, the United Kingdom.
Pharma Mar logo

Pharma Mar

OTCMKTS:PHMMF
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.